WO2011137571A1 - Anticorps rvfab5 neutralisant d'origine humaine contre la glycoprotéine du virus de la rage - Google Patents
Anticorps rvfab5 neutralisant d'origine humaine contre la glycoprotéine du virus de la rage Download PDFInfo
- Publication number
- WO2011137571A1 WO2011137571A1 PCT/CN2010/001576 CN2010001576W WO2011137571A1 WO 2011137571 A1 WO2011137571 A1 WO 2011137571A1 CN 2010001576 W CN2010001576 W CN 2010001576W WO 2011137571 A1 WO2011137571 A1 WO 2011137571A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- rabies virus
- human
- gene
- rabies
- Prior art date
Links
- 230000003472 neutralizing effect Effects 0.000 title claims abstract description 25
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 title abstract description 18
- 206010037742 Rabies Diseases 0.000 claims abstract description 40
- 239000003814 drug Substances 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 50
- 241000700605 Viruses Species 0.000 claims description 31
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 108090000288 Glycoproteins Proteins 0.000 claims description 11
- 102000003886 Glycoproteins Human genes 0.000 claims description 11
- 239000013604 expression vector Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 7
- 238000011282 treatment Methods 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 241000711798 Rabies lyssavirus Species 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 24
- 238000000034 method Methods 0.000 description 14
- 238000010166 immunofluorescence Methods 0.000 description 13
- 241000701447 unidentified baculovirus Species 0.000 description 13
- 239000012634 fragment Substances 0.000 description 12
- 241000238631 Hexapoda Species 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 239000002245 particle Substances 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 9
- 238000003556 assay Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000010353 genetic engineering Methods 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 229940125644 antibody drug Drugs 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940118700 human rabies immune globulin Drugs 0.000 description 3
- 238000012917 library technology Methods 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035049 Blood-Borne Infections Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 241000724252 Cucumber mosaic virus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 101150039660 HA gene Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 229940124861 Rabies virus vaccine Drugs 0.000 description 1
- 241000724205 Rice stripe tenuivirus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000013320 baculovirus expression vector system Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000002064 post-exposure prophylaxis Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960003127 rabies vaccine Drugs 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
La présente invention concerne un anticorps RVFab5 neutralisant d'origine humaine contre la glycoprotéine du virus de la rage. La présente invention concerne également l'emploi de l'anticorps dans la fabrication d'un médicament destiné au traitement prophylactique ou thérapeutique de la rage.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010170856.5 | 2010-05-06 | ||
| CN2010101708565A CN101812130B (zh) | 2010-05-06 | 2010-05-06 | 人源抗狂犬病毒糖蛋白中和性抗体(RVFab5) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2011137571A1 true WO2011137571A1 (fr) | 2011-11-10 |
Family
ID=42619508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2010/001576 WO2011137571A1 (fr) | 2010-05-06 | 2010-10-09 | Anticorps rvfab5 neutralisant d'origine humaine contre la glycoprotéine du virus de la rage |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101812130B (fr) |
| WO (1) | WO2011137571A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013174003A1 (fr) * | 2012-05-24 | 2013-11-28 | Mountgate Group Limited | Compositions et procédés associés à la prévention et au traitement d'une infection rabique |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101812130B (zh) * | 2010-05-06 | 2012-07-04 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗狂犬病毒糖蛋白中和性抗体(RVFab5) |
| CN103998059B (zh) * | 2011-09-30 | 2016-01-20 | 赛特瑞恩股份有限公司 | 用于中和狂犬病病毒的结合分子 |
| CN103505729B (zh) * | 2013-05-24 | 2015-10-28 | 华北制药集团新药研究开发有限责任公司 | 一种稳定的狂犬病毒人源抗体组合制剂 |
| CN114920835B (zh) * | 2021-05-08 | 2024-01-02 | 南昌大学 | 一种高亲和力抗狂犬病病毒的全人源单克隆抗体及其用途 |
| CN113501873B (zh) * | 2021-07-07 | 2023-05-23 | 高光 | Rbv的蛋白结合分子及其用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101133158A (zh) * | 2005-02-02 | 2008-02-27 | 马萨诸塞州大学 | 人抗狂犬病抗体及其用途 |
| CN101550189A (zh) * | 2008-04-25 | 2009-10-07 | 中国人民解放军军事医学科学院卫生学环境医学研究所 | 人源抗狂犬病毒糖蛋白中和性基因工程抗体rd9及其制备与应用 |
| CN101812130A (zh) * | 2010-05-06 | 2010-08-25 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗狂犬病毒糖蛋白中和性抗体(RVFab5) |
-
2010
- 2010-05-06 CN CN2010101708565A patent/CN101812130B/zh active Active
- 2010-10-09 WO PCT/CN2010/001576 patent/WO2011137571A1/fr active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101133158A (zh) * | 2005-02-02 | 2008-02-27 | 马萨诸塞州大学 | 人抗狂犬病抗体及其用途 |
| CN101550189A (zh) * | 2008-04-25 | 2009-10-07 | 中国人民解放军军事医学科学院卫生学环境医学研究所 | 人源抗狂犬病毒糖蛋白中和性基因工程抗体rd9及其制备与应用 |
| CN101812130A (zh) * | 2010-05-06 | 2010-08-25 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗狂犬病毒糖蛋白中和性抗体(RVFab5) |
Non-Patent Citations (1)
| Title |
|---|
| Z CHEN ET AL.: "The Development of Neutralizing Human Antibodies against Rabies Virus.", CHINESE JOURNAL OF VIROLOGY., vol. 26, no. 4, July 2010 (2010-07-01), pages 271 - 275 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013174003A1 (fr) * | 2012-05-24 | 2013-11-28 | Mountgate Group Limited | Compositions et procédés associés à la prévention et au traitement d'une infection rabique |
| EP2855521A1 (fr) * | 2012-05-24 | 2015-04-08 | Mountgate Group Limited | Compositions et procédés associés à la prévention et au traitement d'une infection rabique |
| CN104603149A (zh) * | 2012-05-24 | 2015-05-06 | 万机集团有限公司(英国) | 与预防和治疗狂犬病感染相关的组合物和方法 |
| EP2855521A4 (fr) * | 2012-05-24 | 2016-03-02 | Mountgate Group Ltd | Compositions et procédés associés à la prévention et au traitement d'une infection rabique |
| US9290564B2 (en) | 2012-05-24 | 2016-03-22 | Mountgate Group Limited | Compositions and methods related to the prevention and treatment of rabies infection |
| EP3508497A1 (fr) * | 2012-05-24 | 2019-07-10 | Mountgate Group Limited | Compositions et procédés associés à la prévention et au traitement d'une infection rabique |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101812130B (zh) | 2012-07-04 |
| CN101812130A (zh) | 2010-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111620945B (zh) | 一种抗新型冠状病毒的单克隆抗体或其衍生体 | |
| WO2011137570A1 (fr) | Anticorps rvfab8 neutralisant d'origine humaine contre la glycoprotéine du virus de la rage | |
| CN111560070B (zh) | 针对新型冠状病毒np蛋白的抗体及其检测应用 | |
| CA2809780C (fr) | Anticorps neutralisant le virus de la grippe et son procede de criblage | |
| CN112794899B (zh) | 一种抗新型冠状病毒的全人源单克隆中和抗体及其应用 | |
| CN110317267B (zh) | 针对狂犬病病毒的双特异性抗体及其用途 | |
| JP2009537147A (ja) | インフルエンザウイルスに対する中和抗体 | |
| CN116063464A (zh) | 冠状病毒的抗体或其抗原结合片段 | |
| AU2020202948A1 (en) | Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus, and use for same | |
| WO2011137571A1 (fr) | Anticorps rvfab5 neutralisant d'origine humaine contre la glycoprotéine du virus de la rage | |
| WO2023168776A1 (fr) | Anticorps humanisé dirigé contre le nouveau coronavirus à large spectre et son utilisation | |
| JP2023510787A (ja) | 抗ａｎｇｐｔｌ３抗体及びその応用 | |
| WO2010139196A1 (fr) | Anticorps humain anti-interféron alpha humain et son utilisation | |
| WO2011137569A1 (fr) | Anticorps rvfab3 neutralisant humanisé contre la glycoprotéine du virus de la rage | |
| de Carvalho Nicacio et al. | Neutralizing human Fab fragments against measles virus recovered by phage display | |
| Tsui et al. | Isolation of a neutralizing human RSV antibody from a dominant, non-neutralizing immune repertoire by epitope-blocked panning. | |
| Tikunova et al. | The neutralizing human recombinant antibodies to pathogenic Orthopoxviruses derived from a phage display immune library | |
| CN109295002B (zh) | 杂交瘤细胞、单克隆抗体及其制备方法和应用 | |
| TW201922778A (zh) | 中和性抗體的高通量篩選方法、由該方法製備之中和性抗體，以及其用途 | |
| CN114456264B (zh) | 一种新型冠状病毒稀有广谱表位的人源抗体及其应用 | |
| WO2021233433A1 (fr) | Anticorps monoclonal anti-protéine de spicule du sars-cov-2 | |
| Ando et al. | Construction of human Fab library and isolation of monoclonal Fabs with rabies virus‐neutralizing ability | |
| CN115925904B (zh) | 一种新冠病毒单克隆中和抗体及其应用 | |
| CN115960218B (zh) | 一种抗新型冠状病毒的抗体及其用途 | |
| WO2023046039A1 (fr) | Anticorps monoclonal de protéine de spicule e484q anti-sars-cov-2 et son utilisation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10850941 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 10850941 Country of ref document: EP Kind code of ref document: A1 |